Max Yates1, Alex J MacGregor1, Joanna Robson2, Anthea Craven3, Peter A Merkel4, Raashid A Luqmani3, Richard A Watts1. 1. Norwich Medical School, University of East Anglia, Norwich. 2. Bristol Medical School, University of the West of England, Bristol. 3. Nuffield Department of Orthopaedics, University of Oxford, Oxford, UK. 4. Department of Biostatistics and Epidemiology, and Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
Objective: Blindness is a recognized complication of GCA; however, the frequency of and risk factors for this complication have not been firmly established. The aim of this study was to examine the incidence and determinants of blindness in patients with GCA, using a large international cohort. Methods: The analysis was conducted among subjects recruited into the Diagnosis and Classification Criteria in Vasculitis Study. The study captures consecutive patients presenting to clinic-based physicians. New-onset blindness was assessed 6 months after diagnosis by completion of the Vasculitis Damage Index. Logistic regression analysis was used to assess the association between blindness and clinical variables. Results: Of 433 patients with GCA from 26 countries, 7.9% presented with blindness in at least one eye at 6 months. Risk factors identified at baseline for blindness at 6 months were identified and included prevalent stroke [odds ratio (OR) = 4.47, 95% CI: 1.30, 15.41] and peripheral vascular disease (OR = 10.44, 95% CI: 2.94, 37.03). Conclusion: This is the largest study to date of subjects with incident GCA and confirms that blindness remains a common complication of disease and is associated with established vascular disease. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov , NCT01066208.
Objective: Blindness is a recognized complication of GCA; however, the frequency of and risk factors for this complication have not been firmly established. The aim of this study was to examine the incidence and determinants of blindness in patients with GCA, using a large international cohort. Methods: The analysis was conducted among subjects recruited into the Diagnosis and Classification Criteria in Vasculitis Study. The study captures consecutive patients presenting to clinic-based physicians. New-onset blindness was assessed 6 months after diagnosis by completion of the Vasculitis Damage Index. Logistic regression analysis was used to assess the association between blindness and clinical variables. Results: Of 433 patients with GCA from 26 countries, 7.9% presented with blindness in at least one eye at 6 months. Risk factors identified at baseline for blindness at 6 months were identified and included prevalent stroke [odds ratio (OR) = 4.47, 95% CI: 1.30, 15.41] and peripheral vascular disease (OR = 10.44, 95% CI: 2.94, 37.03). Conclusion: This is the largest study to date of subjects with incident GCA and confirms that blindness remains a common complication of disease and is associated with established vascular disease. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov , NCT01066208.
Authors: Max Yates; Robert Luben; Shabina Hayat; Sarah L Mackie; Richard A Watts; Kay-Tee Khaw; Nick J Wareham; Alex J MacGregor Journal: Rheumatology (Oxford) Date: 2020-02-01 Impact factor: 7.580
Authors: Sebastian Unizony; Timothy J McCulley; Robert Spiera; Jinglan Pei; Paris N Sidiropoulos; Jennie H Best; Christine Birchwood; Andrey Pavlov; John H Stone Journal: Arthritis Res Ther Date: 2021-01-06 Impact factor: 5.156
Authors: Allyson C Egan; Andreas Kronbichler; Irmgard Neumann; Alessandra Bettiol; Nicholas Carlson; Maria C Cid; Giacomo Emmi; Seerapani Gopaluni; Lorraine Harper; Thomas Hauser; Mark A Little; Raashid A Luqmani; Alfred Mahr; Mark McClure; Aladdin J Mohammad; Karl Emil Nelveg-Kristensen; Sophie Ohlsson; Chen Au Peh; Matthew Rutherford; Beatriz Sanchez Alamo; Jennifer Scott; Mårten Segelmark; Rona M Smith; Wladimir M Szpirt; Gunnar Tomasson; Giorgio Trivioli; Augusto Vaglio; Michael Walsh; Maria Wester Trejo; Kerstin Westman; Ingeborg M Bajema; David R W Jayne Journal: Kidney Int Rep Date: 2022-05-25
Authors: Javier Loricera; Santos Castañeda; Clara Moriano; Javier Narváez; Vicente Aldasoro; Olga Maiz; Rafael Melero; Ignacio Villa; Paloma Vela; Susana Romero-Yuste; José L Callejas; Eugenio de Miguel; Eva Galíndez-Agirregoikoa; Francisca Sivera; Jesús C Fernández-López; Carles Galisteo; Iván Ferraz-Amaro; Julio Sánchez-Martín; Lara Sánchez-Bilbao; Mónica Calderón-Goercke; Alfonso Casado; José L Hernández; Miguel A González-Gay; Ricardo Blanco Journal: Ther Adv Musculoskelet Dis Date: 2022-07-22 Impact factor: 3.625
Authors: Kornelis S M van der Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A Bos; Wayel H Abdulahad; Coen A Stegeman; Peter Heeringa; Abraham Rutgers; Cees G M Kallenberg; Annemieke M H Boots; Elisabeth Brouwer Journal: Arthritis Rheumatol Date: 2018-07-30 Impact factor: 10.995